Lupin's Pithampur unit gets Health Canada clearance
In November 2017, Lupin had received warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
By PTI |
NEW DELHI: Drug firm Lupin Ltd today said its Pithampur unit 2 manufacturing facility located in Indore has been cleared by Health Canada after a review.
"Following the review, Health Canada has maintained the compliant rating for unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'," Lupin said in a BSE filing.
In November 2017, Lupin had received warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
Shares of Lupin were trading 2.32 per cent higher at Rs 753.45 on BSE.
"Following the review, Health Canada has maintained the compliant rating for unit 2 at Pithampur (Indore) and has issued a revised 'Establishment License'," Lupin said in a BSE filing.
In November 2017, Lupin had received warning letter from US Food and Drug Administration for its manufacturing facilities in Goa and Pithampur, Indore.
Shares of Lupin were trading 2.32 per cent higher at Rs 753.45 on BSE.
Start a SIP with as low as ₹500 with ET Money App!
Download
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.
Related Articles
Biocon arm gets Health Canada nod for fungal infection treatment injectionADVERTISEMENT
